To confirm that the enhanced anti‐cancer activity of cabazitaxel, combined with CLU silencing, resulted from altered mitotic activity, we quantitated the number of cells displaying mitotic nuclei or multiple nuclei at various doses of cabazitaxel +/− CLU‐KD. This evidence concerns the gene CLU and cancer.